Bookmark and Share

Infinity Pharmaceuticals Shares Rally on Positive Clinical Trial Data (INFI)

Shares of Infinity Pharmaceuticals Inc. (NASDAQ: INFI), a drug discovery and development company, are soaring in trading today after the company reported new data from its ongoing Phase 1, open-label, dose-escalation trial of IPI-145 in patients with advanced hematologic malignancies.

IPI-145 is INFI’s potent oral inhibitor of phophoinositide 3-kinase (P13K)-delta and P13K-gamma. The company said that initial data from the study demonstrated that IPI-145 was well tolerated to date and clinically active in patients with both B-cell and T-cell malignancies, including chronic lymphocytic leukemia, indolent non-Hodgkin’s lymphoma, mantle cell lymphoma, Hodgkin’s lymphoma and T-cell lymphoma. INFI presented the findings from the study at the 54th Annual Meeting of the American Society for Hematology (ASH) in Atlanta, Georgia.

Julian Adams, Ph.D., President of R&D at Infinity, said that the results reinforce INFI’s enthusiasm for IPI-145. Adams further said that the company believes that the potency and activity of IPI-145 against both P13K-delta and P13K-gamma contribute to its potential to become the best-in-class P13K inhibitor for the treatment of hematologic malignances.

Last month, INFI had reported its third-quarter financial results. At the end of the third quarter, INFI had cash, cash equivalents and available-for-sale securities of $189.4 million.

INFI shares have risen sharply in trading today. The stock hit a 52-week high of $27.57 in trading today. At last check, INFI shares were trading 21.60% higher at $27.39 on above average volume of 3.45 million. Year-to-date, the stock has gained more than 240%.


Leave a Reply

  

  

  

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>


-------------------------------------------------------------------------------------------------------------------------
All stories in DailyStocks.com are for informational purposes only. This is NOT a stock recommendation. This DailyStocks.com story is a daily light analysis featuring a stock with insider buying. With some caveats, insiders purchase a stock because they think the stock is going up. There are other factors to consider such as size of the transaction relative to their compensation and net worth. Sometimes, insiders might be propping a stock price up for future financing. Sometimes, the amount of insider buying are misread or misreported. Each month, DailyStocks releases a a summary of the stocks with insider buying. Sign up for the free monthly newsletter at DailyStocks.com . About Dailystocks.com: DailyStocks.com is the place where you can find stories about stocks with insider buying, where you can educate yourself about stock market investing, and where you can perform the stock search engine analysis – you enter a stock symbol, and you get a resulting page of stock ticker indexed links so that you do not have to type the stock symbol each time.